Healthcare Industry News: CytoCore
News Release - February 23, 2006
CytoCore Announces Licensing the First Drug Delivery System That Therapeutically Addresses Cervical Cancer LesionsCHICAGO--(HSMN NewsFeed)--Feb. 23, 2006--CytoCore, Inc. (OTCBB: MCDG.OB ) today announced that it has licensed from University Hospitals of Cleveland a new Drug Delivery System (DDS) developed by physician George Gorodeski, M.D., Ph.D., that will for the first time give the physicians the ability to apply FDA approved drugs to existing cervical lesions.
The DDS is comprised of an applicator handle and drug-delivery modality in the form of a patch that provides a timed-release delivery of the therapeutic agent directly to the surface of the cervix. The handle is a further development of CytoCore's e2 Collector handle, which has been specifically designed to quickly, safely and accurately position and deposit the patch on the cervix.
Current Pap screening programs often find the presence of cervical dysplasia or lesions in early stages. The present treatment options are either surgical removal of the lesion, or repeated follow-ups with Pap testing. While only a fraction of cervical dysplasia cases progress to invasive cervical cancer, the atmosphere of medical uncertainty on a finding of dysplasia, and the limited treatment options (surgery or wait) place an unnecessary burden on the physicians and their patients, and could explain, in part, the rising number of cervical surgeries, some of which may be unnecessary.
Abnormally growing cervical cells, including dysplastic cells, can be treated with different types of anti-viral or other inhibiting medications to control their growth. Early attempts at applying such drugs to cervical lesions typically led to unacceptable toxic effects to the surrounding tissues, so the practice was abandoned. The new DDS will, for the first time, offer the physician a therapeutic treatment option for cervical lesions. This new device will allow for a drug or combination(s) of FDA approved drugs to be applied directly and specifically to the cervix. CytoCore believes that the nature of the device patent filed will allow for the drug manufacturer to file for a new use patent on the drugs used with the patch.
Dr. David Weissberg, CytoCore's CEO stated, "Currently, the limited surgical treatment option for cervical lesions produces an unnecessary risk and burden on the patient and the physician. This new device will give the physician a simple, proven, safe way to treat a cervical lesion. Because of the gradual steady pace of drug release by the patch, proven drugs can be chosen which should produce a locally potent effect on the lesion, but should limit adverse systemic or toxic side effects on neighboring tissues. This product will provide an effective non-surgical therapeutic solution for the huge gap in treatment that exists when dealing with precancerous cervical lesions. We are very excited with how this product expands and completes CytoCore's InPath System. With this product, we have the only end to end product solutions in this sector. The InPath System includes cell collection, identification, localization, and now treatment of cervical dysplasia."
Dr. George Gorodeski stated, "With the support of UHC, I have been working on this device for several years, and I am delighted for the opportunity to bring this product forward with CytoCore's help. CytoCore's energy and momentum make them the perfect partner as this product is designed to complement the InPath System. We expect to begin development of the applicator handle, and will be working with pharmaceutical manufacturers to develop and test a variety of drug combinations that would be appropriate for the patch. I would anticipate entering trials on this product before the end of the year."
About University Hospitals Health System
University Hospitals Health System is the region's premier healthcare delivery system, serving patients at more than 150 locations throughout northern Ohio. Committed to advanced care and advanced caring, University Hospitals Health System offers the region's largest network of primary care physicians, outpatient centers and hospitals. The System also includes a network of specialty care physicians, skilled nursing, elder health, behavioral health, rehabilitation and home care services, managed care and insurance programs and occupational health and wellness. The Health System's tertiary medical center, University Hospitals of Cleveland, is an affiliate of Case Western Reserve University. Together, they form the largest center for biomedical research in the State of Ohio; included are Rainbow Babies & Children's Hospital, among the nation's best children's hospitals; Ireland Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center (the nation's highest designation); and MacDonald Women's Hospital, Ohio's only hospital for women. Nearly 25,000 physicians and employees comprise University Hospitals Health System and its partner hospitals, ranking it northern Ohio's second largest employer. University Hospitals Health System's goal is to provide comprehensive primary and community-based care-the kind of healthcare people need most-as well as access to the highest quality specialty care when necessary.
More information is available at: http://www.uhhs.com/
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005 and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.